Ardelyx Inc. (ARDX)
| Bid | 4.73 |
| Market Cap | 1.31B |
| Revenue (ttm) | 333.62M |
| Net Income (ttm) | -39.14M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -32.24 |
| Forward PE | 22.1 |
| Analyst | Buy |
| Ask | 5 |
| Volume | 5,303,649 |
| Avg. Volume (20D) | 4,525,019.8 |
| Open | 5.51 |
| Previous Close | 5.50 |
| Day's Range | 5.39 - 5.64 |
| 52-Week Range | 4.02 - 9.33 |
| Beta | 0.81 |
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult pat...
Analyst Forecast
According to 9 analyst ratings, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 91.61% from the latest price.
Stock ForecastsEarnings Surprise
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong...
2 months ago · seekingalpha.com
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion ...
